191 related articles for article (PubMed ID: 29878859)
1.
Wei X; Hindle M; Kaviratna A; Huynh BK; Delvadia RR; Sandell D; Byron PR
J Aerosol Med Pulm Drug Deliv; 2018 Dec; 31(6):358-371. PubMed ID: 29878859
[No Abstract] [Full Text] [Related]
2. In vitro tests for aerosol deposition. III: effect of inhaler insertion angle on aerosol deposition.
Delvadia RR; Longest PW; Hindle M; Byron PR
J Aerosol Med Pulm Drug Deliv; 2013 Jun; 26(3):145-56. PubMed ID: 23025452
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Bio-relevant Mouth-Throat Models for Characterization of Metered Dose Inhalers.
Kaviratna A; Tian G; Liu X; Delvadia R; Lee S; Guo C
AAPS PharmSciTech; 2019 Feb; 20(3):130. PubMed ID: 30815748
[TBL] [Abstract][Full Text] [Related]
4. In Vitro Tests for Aerosol Deposition. V: Using Realistic Testing to Estimate Variations in Aerosol Properties at the Trachea.
Wei X; Hindle M; Delvadia RR; Byron PR
J Aerosol Med Pulm Drug Deliv; 2017 Oct; 30(5):339-348. PubMed ID: 28332899
[TBL] [Abstract][Full Text] [Related]
5. An Exploration of Factors Affecting
Ruzycki CA; Martin AR; Finlay WH
J Aerosol Med Pulm Drug Deliv; 2019 Dec; 32(6):405-417. PubMed ID: 31418632
[No Abstract] [Full Text] [Related]
6. In Vitro Tests for Aerosol Deposition. IV: Simulating Variations in Human Breath Profiles for Realistic DPI Testing.
Delvadia RR; Wei X; Longest PW; Venitz J; Byron PR
J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):196-206. PubMed ID: 26447531
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the Respimat Soft Mist Inhaler using a concurrent CFD and in vitro approach.
Worth Longest P; Hindle M
J Aerosol Med Pulm Drug Deliv; 2009 Jun; 22(2):99-112. PubMed ID: 18956950
[TBL] [Abstract][Full Text] [Related]
8. Higher lung deposition with Respimat Soft Mist inhaler than HFA-MDI in COPD patients with poor technique.
Brand P; Hederer B; Austen G; Dewberry H; Meyer T
Int J Chron Obstruct Pulmon Dis; 2008; 3(4):763-70. PubMed ID: 19281091
[TBL] [Abstract][Full Text] [Related]
9. In vitro tests for aerosol deposition II: IVIVCs for different dry powder inhalers in normal adults.
Delvadia R; Hindle M; Longest PW; Byron PR
J Aerosol Med Pulm Drug Deliv; 2013 Jun; 26(3):138-44. PubMed ID: 22947131
[TBL] [Abstract][Full Text] [Related]
10. Factors Determining In Vitro Lung Deposition of Albuterol Aerosol Delivered by Ventolin Metered-Dose Inhaler.
Biswas R; Hanania NA; Sabharwal A
J Aerosol Med Pulm Drug Deliv; 2017 Aug; 30(4):256-266. PubMed ID: 28157430
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers.
Hochrainer D; Hölz H; Kreher C; Scaffidi L; Spallek M; Wachtel H
J Aerosol Med; 2005; 18(3):273-82. PubMed ID: 16181002
[TBL] [Abstract][Full Text] [Related]
12. Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler.
Pitcairn G; Reader S; Pavia D; Newman S
J Aerosol Med; 2005; 18(3):264-72. PubMed ID: 16181001
[TBL] [Abstract][Full Text] [Related]
13. In vivo-in vitro comparison of deposition in three mouth-throat models with Qvar and Turbuhaler inhalers.
Zhang Y; Gilbertson K; Finlay WH
J Aerosol Med; 2007; 20(3):227-35. PubMed ID: 17894531
[TBL] [Abstract][Full Text] [Related]
14. In vitro dose comparison of Respimat
Ciciliani AM; Langguth P; Wachtel H
Int J Chron Obstruct Pulmon Dis; 2017; 12():1565-1577. PubMed ID: 28603412
[TBL] [Abstract][Full Text] [Related]
15. Validation of a general in vitro approach for prediction of total lung deposition in healthy adults for pharmaceutical inhalation products.
Olsson B; Borgström L; Lundbäck H; Svensson M
J Aerosol Med Pulm Drug Deliv; 2013 Dec; 26(6):355-69. PubMed ID: 23421897
[TBL] [Abstract][Full Text] [Related]
16. Effects of generation time on spray aerosol transport and deposition in models of the mouth-throat geometry.
Worth Longest P; Hindle M; Das Choudhuri S
J Aerosol Med Pulm Drug Deliv; 2009 Jun; 22(2):67-83. PubMed ID: 18956949
[TBL] [Abstract][Full Text] [Related]
17. Comparison of in vitro deposition of pharmaceutical aerosols in an idealized child throat with in vivo deposition in the upper respiratory tract of children.
Ruzycki CA; Golshahi L; Vehring R; Finlay WH
Pharm Res; 2014 Jun; 31(6):1525-35. PubMed ID: 24395403
[TBL] [Abstract][Full Text] [Related]
18. In Vitro and In Silico Investigations on Drug Delivery in the Mouth-Throat Models with Handihaler®.
Huang F; Zhou X; Dai W; Yu J; Zhou Z; Tong Z; Yu A
Pharm Res; 2022 Nov; 39(11):3005-3019. PubMed ID: 36071350
[TBL] [Abstract][Full Text] [Related]
19. In vitro monodisperse aerosol deposition in a mouth and throat with six different inhalation devices.
DeHaan WH; Finlay WH
J Aerosol Med; 2001; 14(3):361-7. PubMed ID: 11693848
[TBL] [Abstract][Full Text] [Related]
20. Computationally efficient analysis of particle transport and deposition in a human whole-lung-airway model. Part II: Dry powder inhaler application.
Kolanjiyil AV; Kleinstreuer C; Sadikot RT
Comput Biol Med; 2017 May; 84():247-253. PubMed ID: 27836120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
